Lv4
460 积分 2022-10-26 加入
First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lung
1个月前
已关闭
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
1个月前
已完结
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis
1个月前
已完结
MRGPRX2 Antagonist Treatment Prevents Inflammation and Disease in a Mouse Model of Atopic Dermatitis
1个月前
已完结
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice
1个月前
已完结
Tu1283 PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL MOLECULE INHIBITOR TARGETING THE INTEGRIN α4β7 FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES (IBD)
1个月前
已完结
P102 A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease
2个月前
已完结
Tu1283 PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL MOLECULE INHIBITOR TARGETING THE INTEGRIN α4β7 FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES (IBD)
2个月前
已完结
Modeling relationship of pharmacokinetics, in vitro potency, and α4β7 receptor occupancy with intestinal cell trafficking in a gut-homing mouse model of IBD with MORF-057
2个月前
已关闭
DOP50 Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
2个月前
已关闭
皖公网安备34019202002308
